A major breakthrough in our understanding of PAH was the discovery of genetic mutations predisposing individuals to the disease, particularly heterozygous loss-of-function mutations in the bone morphogenetic protein receptor type 2 (BMPR2) gene. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.